Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-226-6 | CAS number: 13701-70-7
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral, inhalative and dermal toxicity:
According to Regulation (EC) 1907/2009 Annex VIII point 8.5 column 2, the study on acute toxicity via the oral, inhalation and dermal route should not be conducted since divanadium tris(sulphate) is corrosive to the skin (pH < 0).
Justification for classification or non-classification
No (valid) studies are available in the literature that states that divanadium tris(sulphate) should be classified as acutely toxic via ingestion, inhalation and after contact with skin. However, since divanadium tris(sulphate) is classified as corrosive to skin, Cat. 1B and classified as seriously damage to eyes by worst case considerations (pH < 2), in-vivo acute toxicity studies do not need to be conducted in accordance with section 8.5, column 2, Annex VIII of Regulation (EC) 1907/2006.
Since, there is no evidence that divanadium tris(sulphate) is acutely toxic via ingestion, inhalation and after contact with skin, divanadium tris(sulphate) should not be classified as acutely toxic.
Specific target organ toxicant (STOT) – single exposure
The classification criteria according to Regulation (EC) 1272/2008 as specific target organ toxicant (STOT) – single exposure, oral, inhalation, or dermal are not met (see discussion above). Hence, no C&L is required for divanadium tris(sulphate).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
